Abstract:Objective. Casticin is generally used in traditional herbal medicine for its anti-inflammatory and anticarcinogenic pharmacological properties. Also, microRNAs are indispensable oncogenes or cancer suppressors being dysregulated in various diseases. In this study, we aimed to elucidate the mechanisms underlying effects of casticin on the progression of acute myeloid leukemia (AML). Methods. CCK-8 and flow cytometry were utilized to measure the proliferation and apoptosis of AML cell lines, respectively, after treatment with different concentrations of casticin. The alteration of several microRNA expressions in response to casticin treatment was detected by performing qRT-PCR, and the activity of PI3K/Akt pathways was evaluated through immunoblotting. Afterwards, the potential target gene of miR-338-3p was investigated by dual-luciferase reporter assay. In order to evaluate the role of miR-338-3p in the casticin-induced cellular phenotype changes, AML cells were transfected with miR-338-3p mimics or inhibitor and then subjected to proliferation and apoptosis analysis. Finally, a mouse xenograft model system was employed to investigate the role of casticin in AML progression in vivo. Results. Suppressed cellular proliferation and enhanced apoptosis were observed in HL-60 and THP-1 cells after exposure to casticin, accompanied by remarkable upregulation of the miR-338-3p expression as well as a decline in the phosphorylation of PI3K and Akt proteins. RUNX2 was identified as a direct target molecular of miR-338-3p, which might account for the findings that miR-338-3p knockdown enhanced the PI3K/Akt pathway activity, whereas the miR-338-3p overexpression inactivated this signaling pathway. In addition, the inhibition of the miR-338-3p expression attenuated severe cell apoptosis and suppressions of PI3K/Akt pathway induced by casticin. Furthermore, casticin treatment retarded tumor growth rate in mouse models, whilst elevating miR-338 expression and repressing the activity of PI3K/Akt pathway in vivo. However, miR-338-3p depletion could also abolish the phenotypic alterations caused by casticin treatment. Conclusion. Casticin promotes AML cell apoptosis but inhibits AML cell proliferation in vitro and tumor growth in vivo by upregulating miR-338-3p, which targets RUNX2 and thereafter inactivates PI3K-Akt signaling pathway. Our results provide insights into the mechanisms underlying the action of casticin in the control of AML progression.

Mir-148A-3p Suppresses the Progression of Acute Myeloid Leukemia Via Targeting Cyclin-Dependent Kinase 6 (CDK6).

Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?

miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway

Mir-638 Regulates Differentiation and Proliferation in Leukemic Cells by Targeting Cyclin-dependent Kinase 2*

MiR-335-3p Inhibits Cell Proliferation and Induces Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia by Targeting EIF3E

Mir-181A Post-Transcriptionally Downregulates Oncogenic RalA and Contributes to Growth Inhibition and Apoptosis in Chronic Myelogenous Leukemia (CML)

MicroRNA-206 Serves As a Tumor Suppressor in Pediatric Acute Myeloid Leukemia by Targeting Cyclin D1.

Mir-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit the proliferation and induce apoptosis of leukemia cells.

Long Non-Coding RNA LINC01018 Inhibits the Progression of Acute Myeloid Leukemia by Targeting Mir-499A-5p to Regulate PDCD4.

MiR-20a-5p Functions As a Potent Tumor Suppressor by Targeting PPP6C in Acute Myeloid Leukemia

Epigenetic Silencing Of Mir-218 Regulates Cdk6 Expression In Pre-B Acute Lymphoblastic Leukemia Cells

miR-338-3p Plays a Significant Role in Casticin-Induced Suppression of Acute Myeloid Leukemia via Targeting PI3K/Akt Pathway

Mir-223 Decreases Cell Proliferation and Enhances Cell Apoptosis in Acute Myeloid Leukemia Via Targeting FBXW7.

MiR-1306-5p promotes cell proliferation and inhibits cell apoptosis in acute myeloid leukemia by downregulating PHF6 expression

Matrine regulates miR‐495‐3p/miR‐543/PDK1 axis to repress the progression of acute myeloid leukemia via the Wnt/β‐catenin pathway

LncRNA HOTAIRM1 is Involved in the Progression of Acute Myeloid Leukemia Through Targeting Mir-148B.

The Tumor Suppressive Role of Mirna-370 by Targeting FoxM1 in Acute Myeloid Leukemia.

miR‐345‐5p regulates proliferation, cell cycle, and apoptosis of acute myeloid leukemia cells by targeting AKT2

CLPs-miR-103a-2-5p inhibits proliferation and promotes cell apoptosis in AML cells by targeting LILRB3 and Nrf2/HO-1 axis, regulating CD8 + T cell response

Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway